BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has been launched in Japan for the treatment of early ...
Still looking? See more results on Wirecutter. We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Dave Gershgorn Dave Gershgorn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results